The Joint (JYNT) Upgraded by Zacks Investment Research to Buy
Zacks Investment Research upgraded shares of The Joint (NASDAQ:JYNT) from a hold rating to a buy rating in a research report sent to investors on Saturday. Zacks Investment Research currently has $7.75 price target on the stock.
According to Zacks, “The Joint Corp. is a healthcare franchisor of chiropractic clinics. The Company’s plans include: Single Visit, Premium Wellness Plan and Wellness Plan. It also provides a family wellness plan. The Company also provides removal of subluxations. It operates its clinics across: Albany, New York; Austin, Texas; Brentwood, California; Fort Mill, South Carolina; Lubbock, Texas; Lynnwood, Washington; Middletown, New Jersey; San Antonio, Texas; San Diego, California and Spartanburg, South Carolina, among others. The Joint Corp. is headquartered in Scottsdale, Arizona. “
A number of other equities research analysts have also issued reports on JYNT. ValuEngine raised shares of The Joint from a sell rating to a hold rating in a report on Thursday, March 29th. Maxim Group raised their price target on shares of The Joint from $7.00 to $9.00 and gave the stock a buy rating in a report on Thursday, April 12th. Finally, Lake Street Capital assumed coverage on shares of The Joint in a report on Wednesday, March 28th. They issued a buy rating on the stock. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $7.05.
The Joint (NASDAQ:JYNT) last announced its quarterly earnings results on Thursday, March 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. The business had revenue of $6.93 million for the quarter, compared to analyst estimates of $6.48 million. The Joint had a negative net margin of 13.01% and a negative return on equity of 66.74%. equities research analysts anticipate that The Joint will post 0.08 earnings per share for the current year.
A number of institutional investors have recently made changes to their positions in JYNT. Deutsche Bank AG grew its holdings in The Joint by 3,839.1% in the 4th quarter. Deutsche Bank AG now owns 59,087 shares of the company’s stock worth $293,000 after acquiring an additional 57,587 shares during the last quarter. Renaissance Technologies LLC bought a new stake in The Joint in the 4th quarter worth $379,000. Russell Investments Group Ltd. grew its holdings in The Joint by 28.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 112,900 shares of the company’s stock worth $538,000 after acquiring an additional 25,000 shares during the last quarter. Finally, Skylands Capital LLC grew its holdings in The Joint by 11.0% in the 4th quarter. Skylands Capital LLC now owns 612,529 shares of the company’s stock worth $3,038,000 after acquiring an additional 60,900 shares during the last quarter. 49.57% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “The Joint (JYNT) Upgraded by Zacks Investment Research to Buy” was originally published by Daily Political and is the property of of Daily Political. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/04/17/the-joint-jynt-upgraded-by-zacks-investment-research-to-buy.html.
The Joint Company Profile
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of December 31, 2017, the company operated 352 franchised clinics and 47 company-owned or managed clinics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for The Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Joint and related companies with MarketBeat.com's FREE daily email newsletter.